Emergence of decreased susceptibility to extended-spectrum cephalosporins in neisseria gonorrhoeae in india

National Medical Journal of India

Volumn 26, Issue 1, 2013, Pages 26-28

  Sood, S ^a   Mahajan, N ^a   Verma, R ^a   Kar, H K ^b   Sharma, V K ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b DR RAM MANOHAR LOHIA HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEFPODOXIME; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; EXTENDED SPECTRUM CEPHALOSPORIN; NALIDIXIC ACID; PENICILLIN DERIVATIVE; SPECTINOMYCIN; TETRACYCLINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CALIBRATION; DISK DIFFUSION; FEMALE; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA GONORRHOEAE; SEXUALLY TRANSMITTED DISEASE;

ANTI-BACTERIAL AGENTS; CEFTIZOXIME; CEFTRIAXONE; CIPROFLOXACIN; INDIA; MICROBIAL SENSITIVITY TESTS; NALIDIXIC ACID; NEISSERIA GONORRHOEAE; PENICILLINS; SPECTINOMYCIN; TETRACYCLINE;

EID: 84879321692     PISSN: 0970258X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Workowski KA, Berman SM, Douglas JMJ. Emerging antimicrobial resistance in Neisseria gonorrhoeae: Urgent need to strengthen prevention strategies. Ann Intern Med 2008;148:606-13.
2. World Health Organization, Department of HIV/AIDS. Global prevalence and incidence of selected curable sexually transmitted infections: Overview and estimates. Geneva, Switzerland: WHO; 2001.
3. World Health Organization, Department of Reproductive Health and Research. Prevalence and incidence of selected sexually transmitted infections, WHO: Geneva, Switzerland; 2011. Available at http://www.who.int/reproductivehealth/publications/rtis/9789241502450/en/index.html.
4. World Health Organization, Department of Reproductive Health and Research. Emergence of multi-drug resistant Neisseria gonorrhoeae - threat of global rise in untreatable sexually transmitted infections. Geneva, Switzerland: WHO; 2011.
5. Kugelman G, Tapsall JW, Goire N, Syrmis MW, Limnios A, Lambert SB, et al. Simple, rapid, and inexpensive detection of Neisseria gonorrhoeae resistance mechanisms using heat-denatured isolates and SYBR green-based real-time PCR. Antimicrob Agents Chemother 2009;53:4211-16.
6. Centers for Disease Control and Prevention (CDC). Cephalosporin susceptibility among Neisseria gonorrhoeae isolates-United States, 2000-2010. MMWR Morb Mortal Wkly Rep 2011;60:873-7.
7. Unemo M, Golparian D, Syversen G, Vestrheim DF, Moi H. Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010. Euro Surveill 2010;15:pii=19721.
8. Ison CA, Hussey J, Sankar KN, Evans J, Alexander S. Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. Euro Surveill 2011;16:pii=19833.0
9. M, Golparian D, Stary A, Eigentler A. First Neisseria gonorrhoeae strain with resistance to cefixime causing gonorrhoea treatment failure in Austria, 2011. Euro Surveill. 2011; 16:pii=19998.
10. Ohnishi M, Saika T, Hoshina S, Iwasaku K, Nakayama S, Watanabe H, et al. Ceftriaxone-resistant Neisseria gonorrhoeae, Japan. Emerg Infect Dis 2011;17:148-9.
11. Barry PM, Klausner JD. The use of cephalosporins for gonorrhea: The impending problem of resistance. Expert Opin Pharmacother 2009;10:555-77.
12. Bala M, Ray K, Gupta SM, Muralidhar S, Jain RK. Changing trends of antimicrobial susceptibility patterns of Neisseria gonorrhoeae in India and the emergence of ceftriaxone less susceptible N. gonorrhoeae strains. J Antimicrob Chemother 2007; 60:582-6.
13. World Health Organization. Laboratory diagnosis of gonorrhoea. WHO Regional Publication, South-East Asia Series No 33. Geneva: WHO; 1999. Available at http://w3.whosea.org/book33.
14. Bell SM, Pham JN, Fisher GT. Antibiotic susceptibility testing by the CDS method: A manual for medical and veterinary laboratories. Randwick, Australia: The Antibiotic Reference Laboratory, The Prince of Wales Hospital, South Eastern Area Laboratory Services; 2009.
15. Limnios A, Tapsall J, Kahlmeter J, Hogan T, Ray S, Lam A, et al. Cefpodoxime 10 μg disc screening test for detection of Neisseria gonorrhoeae with mosaic PBP2 and decreased susceptibility to extended-spectrum cephalosporins for public health purposes. APMIS 2011;119:356-63.
16. Clinical and Laboratory Standard Institute. Performance standards for antimicrobial susceptibility testing; Seventeenth Informational Supplement. CLSI Document M100-S17. Wayne, Philadelphia: CLSI; 2007.
17. Tapsall JW, Ndowa F, Lewis DA, Unemo M. Meeting the public health challenge of multidrug-and extensively drug-resistant Neisseria gonorrhoeae. Expert Rev Anti Infect Ther 2009;7:821-34.
18. Workowski KA, Berman S; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010;59 (RR-12):1-110.
19. National AIDS Control Organization. National guidelines on prevention, management and control of reproductive tract infections including sexually transmitted infections. Delhi: National AIDS Control Organization, Government of India; 2007:25.
20. Tapsall JW, Phillips EA. The sensitivities of 173 Sydney isolates of Neisseria gonorrhoeae to cefpodoxime and other antibiotics used to treat gonorrhoea. Pathology 1995;27:64-6.